C07K 2317/75
Agonist effect on antigen
C07K2317/75 (Agonist effect on antigen) appears on 1,447 US grants and 3,245 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,447
- Published applications
- 3,245
- Assignees
- 943
- Inventors
- 5,423
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 6 |
| 2003 | 1 | 26 |
| 2004 | 2 | 15 |
| 2005 | 3 | 24 |
| 2006 | 3 | 42 |
| 2007 | 5 | 28 |
| 2008 | 7 | 44 |
| 2009 | 18 | 56 |
| 2010 | 26 | 62 |
| 2011 | 27 | 60 |
| 2012 | 21 | 54 |
| 2013 | 40 | 82 |
| 2014 | 51 | 107 |
| 2015 | 54 | 102 |
| 2016 | 85 | 148 |
| 2017 | 73 | 178 |
| 2018 | 83 | 182 |
| 2019 | 108 | 237 |
| 2020 | 120 | 252 |
| 2021 | 131 | 262 |
| 2022 | 119 | 282 |
| 2023 | 115 | 275 |
| 2024 | 135 | 282 |
| 2025 | 132 | 274 |
| 2026 | 79 | 165 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Monoclonal antibodies against LILRB1 for diagnostic and therapeutic use1 Sep 2026US 12,723,078 B2Board of Regents, The University of Texas System
- Anti-PD-1 antibodies1 Sep 2026US 12,723,079 B2PD-I Acquisition Group, LLC
- Methods of treating cancer using binding molecules that bind CD137 and PD-L11 Sep 2026US 12,723,095 B2Merus N.V.
- Antibody specifically binding to human serum albumin1 Sep 2026US 12,723,101 B2Numab Therapeutics AG
- Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)25 Aug 2026US 12,714,745 B2Baylor Research Institute
- Anti-ox40 antibody and uses thereof8 Oct 2026US 2026/0308267 A1Hutchison Medipharma Limited
- Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns1 Oct 2026US 2026/0297191 A1ImmunoBrain Checkpoint, Inc.
- Anti-cmet antibody1 Oct 2026US 2026/0297202 A1Pierre Fabre Medicament
- Monospecific anti-frizzled antibodies and methods of use24 Sep 2026US 2026/0285987 A1Surrozen Operating, Inc.
- Compositions and methods for treating obesity and reducing fat accumulation10 Sep 2026US 2026/0265369 A1
Most cited
By later US patents
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Monoclonal antibodies to programmed death 1 (PD-1)233US 8,779,105 B2Medarex, Inc. · 2014
- Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)162US 8,383,796 B2Medarex, Inc. · 2013
- Methods for treating cancer using anti-PD-1 antibodies157US 9,084,776 B2E. R. Squibb & Sons, Inc. · 2015